1. India's Generic Semaglutide Flood Cuts Eli Lilly's Lead, Tests Novo Nordisk's Global Patent Strategy
A surge of cheap, generic copies of Novo Nordisk's blockbuster obesity drug semaglutide is rapidly reshaping India's fast-growing market, directly eroding Eli Lilly & Co.'s early-mover advantage. This development offers the first real-world test of how Novo Nordisk's global dominance may fare as its critical patents be...